COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches

[1]  S. Feng,et al.  Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes , 2023, Frontiers in cellular and infection microbiology.

[2]  M. Dadashi,et al.  Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases , 2023, Cell Communication and Signaling.

[3]  M. Alsaffar,et al.  Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects , 2023, Cell Communication and Signaling.

[4]  Adarsh Kesharwani,et al.  Micronutrients/miRs/ATP networking in mitochondria: Clinical intervention with ferroptosis, cuproptosis, and calcium burden. , 2023, Mitochondrion.

[5]  T. Mafort,et al.  High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients , 2023, PloS one.

[6]  M. Scheurer,et al.  HERVs and Cancer—A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers , 2023, Biomedicines.

[7]  A. Hakami,et al.  Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province , 2023, Cureus.

[8]  L. Krishnamurti,et al.  Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin , 2023, Biomedicines.

[9]  C. Bolm,et al.  Beta-Thalassemia Minor and SARS-CoV-2: Physiopathology, Prevalence, Severity, Morbidity, and Mortality , 2023, Thalassemia Reports.

[10]  M. Dhodapkar,et al.  Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies , 2023, Blood Advances.

[11]  F. Lemonnier,et al.  Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies , 2023, Vaccine.

[12]  A. Bárez,et al.  Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group , 2022, Infectious Diseases and Therapy.

[13]  M. Davids,et al.  Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia , 2022, Blood Advances.

[14]  M. Mohty,et al.  Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases , 2022, Bone Marrow Transplantation.

[15]  K. Ramasamy,et al.  Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study , 2022, Hematology.

[16]  Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants , 2022, Blood.

[17]  M. Liaghat,et al.  Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights , 2022, Cell Communication and Signaling.

[18]  D. Bouscary,et al.  Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era , 2022, Viruses.

[19]  A. Jafarzadeh,et al.  Development and exacerbation of autoimmune hemolytic anemia following COVID‐19 vaccination: A systematic review , 2022, International journal of laboratory hematology.

[20]  M. Dhodapkar.  The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception , 2022, American journal of hematology.

[21]  A. Sette,et al.  Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination , 2022, Blood.

[22]  Yue Gao,et al.  GSK3326595 is a promising drug to prevent SARS‐CoV‐2 Omicron and other variants infection by inhibiting ACE2‐R671 di‐methylation , 2022, Journal of medical virology.

[23]  M. Nelen,et al.  Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene , 2022, Blood advances.

[24]  Y. Tong,et al.  Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention , 2022, MedComm.

[25]  Y. Herishanu,et al.  CLL and COVID-19: light at the end of the tunnel? , 2022, Blood.

[26]  J. Ward,et al.  The Influence of Viral Infections on Iron Homeostasis and the Potential for Lactoferrin as a Therapeutic in the Age of the SARS-CoV-2 Pandemic , 2022, Nutrients.

[27]  M. Liaghat,et al.  Possible role of autophagy induced by COVID-19 in cancer progression, chemo-resistance, and tumor recurrence , 2022, Infectious Agents and Cancer.

[28]  D. Xia,et al.  Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19 , 2022, International journal of biological sciences.

[29]  Ali I. Al-Gareeb,et al.  Hemolytic anemia in COVID-19 , 2022, Annals of Hematology.

[30]  Ahmad A. Alharbi,et al.  Coronavirus disease 2019 in patients with sickle cell disease: A cross-sectional study from Jazan Province, Saudi Arabia , 2022, Journal of Nature and Science of Medicine.

[31]  Bahman,et al.  Molecular mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients , 2022, Journal of Trace Elements in Medicine and Biology.

[32]  N. Yousif.  Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis , 2022, Muthanna medical journal.

[33]  M. Levy,et al.  Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations , 2022, bioRxiv.

[34]  E. Dardiotis,et al.  Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns , 2022, Diagnostics.

[35]  K. Plaimas,et al.  Multi-Level Biological Network Analysis and Drug Repurposing Based on Leukocyte Transcriptomics in Severe COVID-19: In Silico Systems Biology to Precision Medicine , 2022, Journal of personalized medicine.

[36]  Dimitra S. Mouliou.  Managing Viral Emerging Infectious Diseases via current Molecular Diagnostics in the Emergency Department: the Tricky Cases , 2022, Expert review of anti-infective therapy.

[37]  E. Dardiotis,et al.  Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? , 2022, Multiple Sclerosis and Related Disorders.

[38]  K. Ibrahim,et al.  Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19 , 2022 .

[39]  A. Lesokhin,et al.  P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS , 2022, HemaSphere.

[40]  L. Sehn,et al.  A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies , 2022, Current oncology.

[41]  M. Hallek,et al.  COVID-19 in patients with hematologic malignancy , 2022, Blood.

[42]  T. Luetkens,et al.  Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy , 2022, Blood.

[43]  K. Nguyen.  Containing the spread of COVID-19 virus facing to its high mutation rate: approach to intervention using a nonspecific way of blocking its entry into the cells , 2022, Nucleosides, nucleotides & nucleic acids.

[44]  I. Hamza,et al.  Molecular Mechanisms of Iron and Heme Metabolism. , 2022, Annual review of nutrition.

[45]  G. Salles,et al.  Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies , 2022, Cancer Cell.

[46]  R. Ogawa,et al.  Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies , 2022, Annals of Hematology.

[47]  Wei-Chen Lin,et al.  The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections , 2022, Frontiers in Immunology.

[48]  William F. Fadel,et al.  Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[49]  M. S. Elshikh,et al.  An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors , 2022, Saudi Journal of Biological Sciences.

[50]  M. Neurath,et al.  SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells , 2022, Cells.

[51]  P. Srivastava,et al.  Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia , 2022, Blood.

[52]  James Batchelor,et al.  Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study , 2022, Nature Cancer.

[53]  C. Hofmeister,et al.  Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  F. Lund-Johansen,et al.  Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination , 2022, British journal of haematology.

[55]  C. Bollard,et al.  Cellular therapies for the treatment and prevention of SARS-CoV-2 infection , 2022, Blood.

[56]  G. Fusco,et al.  Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant , 2022, Viruses.

[57]  U. Ilyas,et al.  Sickle Cell Disease and COVID-19 Infection: Importance of COVID-19 Testing and Approach to Management , 2022, Cureus.

[58]  N. Delgado,et al.  What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19? , 2022, Current Oncology Reports.

[59]  K. Gourgoulianis,et al.  Vulnerability of β-Thalassemia Heterozygotes to COVID-19: Results from a Cohort Study , 2022, Journal of personalized medicine.

[60]  S. Chou,et al.  New presentations and exacerbations of immune thrombocytopenia after coronavirus disease 2019 vaccinations: the Taiwan experience , 2022, Platelets.

[61]  Hesham K. Yosef,et al.  SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism , 2022, Stem Cell Reviews and Reports.

[62]  F. Grosveld,et al.  An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern , 2022, bioRxiv.

[63]  K. Ibrahim,et al.  Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19 , 2022, Molecular Biology Reports.

[64]  E. Holland,et al.  Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells , 2022, bioRxiv.

[65]  S. Rubinstein,et al.  COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments , 2022, Acta Haematologica.

[66]  G. Fasola,et al.  Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave , 2022, PloS one.

[67]  Resmi V. Nair,et al.  Severe Aplastic Anemia After Receiving SARS-CoV-2 Moderna mRNA Vaccination , 2022, Journal of hematology.

[68]  S. Corrao,et al.  COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis , 2022, F1000Research.

[69]  F. Leutmezer,et al.  B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients , 2022, Annals of neurology.

[70]  H. Leier,et al.  A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants , 2022, bioRxiv.

[71]  R. Bruton,et al.  Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia , 2022, Journal of Hematology & Oncology.

[72]  Jie-Li Hu,et al.  Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro , 2022, Emerging microbes & infections.

[73]  B. A. Costa,et al.  Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature , 2022, Hematology, Transfusion and Cell Therapy.

[74]  J. Gribben,et al.  Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus , 2022, ESMO Open.

[75]  E. Lanoy,et al.  Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis , 2022, Leukemia.

[76]  Michael D. Miller,et al.  ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2–specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report , 2021, American Journal of Transplantation.

[77]  J. Tamburini,et al.  Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma , 2021, Blood.

[78]  P. Bolin,et al.  Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene , 2021, RNA biology.

[79]  Maheedhara R. Guda,et al.  PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis , 2021, Biomedicines.

[80]  Wei Yan,et al.  Extracellular vesicles carrying miRNA-181b-5p affects the malignant progression of acute lymphoblastic leukemia , 2021, Journal of Translational Medicine.

[81]  S. Schreiber,et al.  Persister cancer cells: Iron addiction and vulnerability to ferroptosis. , 2021, Molecular cell.

[82]  A. Schreiber,et al.  First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report , 2021, BMC Nephrology.

[83]  N. Askari,et al.  A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2 , 2021, Infection, Genetics and Evolution.

[84]  T. Sonoki,et al.  Severe aplastic anemia after COVID-19 mRNA vaccination: Causality or coincidence? , 2021, Journal of Autoimmunity.

[85]  W. Barcellini,et al.  Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature , 2021, Frontiers in Immunology.

[86]  R. Manhães-de-Castro,et al.  The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle–gut–brain axis and implications for SARS-CoV-2 infection , 2021, Nutrition reviews.

[87]  R. Amin,et al.  Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection , 2021, Pathology.

[88]  T. Duong,et al.  Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature , 2021, Blood Reviews.

[89]  M. Bordbar,et al.  Assessment of the HScore as a predictor of disease outcome in patients with COVID-19 , 2021, BMC Pulmonary Medicine.

[90]  A. Allegra,et al.  Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia , 2021, Frontiers in Immunology.

[91]  M. Ramzi,et al.  MiR-181a and -b expression in acute lymphoblastic leukemia and its correlation with acute graft-versus-host disease after hematopoietic stem cell transplantation, COVID-19 and torque teno viruses , 2021, VirusDisease.

[92]  M. Dimopoulos,et al.  Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist , 2021, American journal of hematology.

[93]  P. Qian,et al.  Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy , 2021, Signal Transduction and Targeted Therapy.

[94]  J. Diallo,et al.  Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern , 2021, ACS infectious diseases.

[95]  S. Abbasian,et al.  The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword , 2021, Molecular biology reports.

[96]  Chai-Eng Tan,et al.  COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes , 2021, Frontiers in Medicine.

[97]  A. McDermott,et al.  AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire , 2021, Science Translational Medicine.

[98]  Katie M. Campbell,et al.  How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. , 2021, Blood cancer discovery.

[99]  Elisabeth F. Heuston,et al.  Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia , 2021, Science Translational Medicine.

[100]  Patrick W. Johnson,et al.  Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies , 2021, Cancer Cell.

[101]  Xianliang Ke,et al.  Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19 , 2021, bioRxiv.

[102]  M. Dimopoulos,et al.  Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study , 2021, Cancers.

[103]  J. Oliveira,et al.  SARS-CoV-2 association with hemoglobin and iron metabolism. , 2021, Revista da Associacao Medica Brasileira.

[104]  A. Alhadidi,et al.  ALL-443: Diagnostic and Prognostic Significance of miRNA-511 and miRNA-16 Expression in Adult B-Acute Lymphoblastic Leukemia Patients , 2021 .

[105]  F. Forouzanfar,et al.  Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK/STAT signaling pathways , 2021, International Immunopharmacology.

[106]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma , 2021, Blood Advances.

[107]  J. Tamburini,et al.  Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients , 2021, medRxiv.

[108]  T. Thum,et al.  Reply to ‘COVID‐19 severity, miR‐21 targets, and common human genetic variation’ , 2021, European journal of heart failure.

[109]  G. B. Karlsson Hedestam,et al.  Immunity to SARS‐CoV‐2 induced by infection or vaccination , 2021, Journal of internal medicine.

[110]  P. Gorello,et al.  Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection , 2021, Frontiers in Pediatrics.

[111]  P. Tiberghien,et al.  Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies , 2021, Annals of Oncology.

[112]  P. Martínez,et al.  Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group , 2021, Leukemia & lymphoma.

[113]  S. Memon,et al.  Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine , 2021, International Journal of Hematology.

[114]  T. Murdych.  A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine , 2021, International journal of laboratory hematology.

[115]  R. Zulli,et al.  COVID-19 in chronic myeloid leukemia patients in Latin America , 2021, Leukemia & lymphoma.

[116]  P. Katsaounou,et al.  Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19 , 2021, Journal of personalized medicine.

[117]  C. Brullo,et al.  Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective , 2021, International journal of molecular sciences.

[118]  R. Siddiqui,et al.  New Onset Aplastic Anemia after a COVID-19 Infection: A Case Report , 2021 .

[119]  O. Wolach,et al.  Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches? , 2021, Hemato.

[120]  R. Vij,et al.  A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab , 2021, Blood Cancer Journal.

[121]  M. Vogel,et al.  On Iron Metabolism and Its Regulation , 2021, International journal of molecular sciences.

[122]  K. Gourgoulianis,et al.  False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives , 2021, Expert review of respiratory medicine.

[123]  M. Scheinberg,et al.  Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor , 2021, Journal of translational autoimmunity.

[124]  L. Morel,et al.  Iron Metabolism: An Under Investigated Driver of Renal Pathology in Lupus Nephritis , 2021, Frontiers in Medicine.

[125]  A. Cortellini,et al.  The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer , 2021, ESMO Open.

[126]  Milad Shirvaliloo,et al.  The role of autophagy in controlling SARS‐CoV‐2 infection: An overview on virophagy‐mediated molecular drug targets , 2021, Cell biology international.

[127]  Caixia Li,et al.  Whole-Transcriptome RNA Sequencing Reveals Significant Differentially Expressed mRNAs, miRNAs, and lncRNAs and Related Regulating Biological Pathways in the Peripheral Blood of COVID-19 Patients , 2021, Mediators of inflammation.

[128]  Der-Yuan Chen,et al.  Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review , 2021, Frontiers in Immunology.

[129]  Feng Zhu,et al.  The miRNA: a small but powerful RNA for COVID-19 , 2021, Briefings Bioinform..

[130]  C. Barber.  Rare health conditions 44: ataxia, Diamond Blackfan anaemia, sexual identities , 2021 .

[131]  M. Elvers,et al.  The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. , 2021, Blood.

[132]  A. Abbasi,et al.  COVID-19 in a Patient with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL): A Case Report , 2021, Journal of Research in Applied and Basic Medical Sciences.

[133]  E. Livingston,et al.  The Johnson & Johnson Vaccine for COVID-19. , 2021, JAMA.

[134]  Thi H. O. Nguyen,et al.  Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection , 2021, PLoS pathogens.

[135]  Y. Shoenfeld,et al.  The SARS-CoV-2 as an instrumental trigger of autoimmunity , 2021, Autoimmunity Reviews.

[136]  D. R. Mathern,et al.  Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine , 2021, Annals of Emergency Medicine.

[137]  M. Martinez,et al.  Plitidepsin: a Repurposed Drug for the Treatment of COVID-19 , 2021, Antimicrobial Agents and Chemotherapy.

[138]  E. Mylonakis,et al.  In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality , 2021, Annals of Internal Medicine.

[139]  F. Lionnet,et al.  Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: case report , 2021, BMC Pulmonary Medicine.

[140]  B. Stockwell,et al.  Ferroptosis: mechanisms, biology and role in disease , 2021, Nature Reviews Molecular Cell Biology.

[141]  N. Saba,et al.  Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy , 2021, Leukemia Research.

[142]  H. Habib,et al.  The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators , 2021, Biomedicine & Pharmacotherapy.

[143]  G. Freddi,et al.  Anemia in patients with Covid-19: pathogenesis and clinical significance , 2021, Clinical and Experimental Medicine.

[144]  A. Kronbichler,et al.  Immunopathogenesis and treatment of cytokine storm in COVID-19 , 2021, Theranostics.

[145]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[146]  P. Emery,et al.  Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters , 2020, Journal of clinical pharmacology.

[147]  Liegang Liu,et al.  Association between iron status and the risk of adverse outcomes in COVID-19 , 2020, Clinical Nutrition.

[148]  Haider Ghazanfar,et al.  A Rare Case of Parvovirus B19 Infection Manifesting as Chronic Aplastic Anemia and Neutropenia in a Human Immunodeficiency Virus-Infected Patient , 2020, Cureus.

[149]  S. Abdin,et al.  The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities , 2020, Infection, Genetics and Evolution.

[150]  W. Barcellini,et al.  New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy , 2020, Journal of clinical medicine.

[151]  Nguyen H. Tran,et al.  T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.

[152]  R. Webby,et al.  Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.

[153]  M. Boccadoro,et al.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia , 2020, Frontiers in Immunology.

[154]  Z. Kučinskienė,et al.  Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood , 2020, International journal of laboratory hematology.

[155]  N. Berger,et al.  When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities , 2020, Blood Reviews.

[156]  Y. Rolland,et al.  Major rise of a chronic lymphoid leukemia clone during the course of COVID‐19 , 2020, International journal of laboratory hematology.

[157]  J. C. Cohen Tervaert,et al.  Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19 , 2020, Blood Advances.

[158]  E. Oteng-Ntim,et al.  COVID‐19 and the pulmonary complications of sickle cell disease , 2020, EJHaem.

[159]  N. Radhakrishnan,et al.  Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia , 2020, Transfusion and Apheresis Science.

[160]  M. Aljurf,et al.  Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection , 2020, Annals of Hematology.

[161]  J. Low,et al.  Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19) , 2020, Nutrition.

[162]  L. Baglietto,et al.  Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 , 2020, Frontiers in Oncology.

[163]  S. Mousa,et al.  Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic , 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[164]  J. C. Cohen Tervaert,et al.  Natural Killer Cell Dysfunction and Its Role in COVID-19 , 2020, International journal of molecular sciences.

[165]  M. Desancho,et al.  Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options , 2020, Journal of blood medicine.

[166]  A. Zelenetz,et al.  Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia , 2020, Leukemia.

[167]  Jingyuan Xie,et al.  Anemia is associated with severe illness in COVID‐19: A retrospective cohort study , 2020, Journal of medical virology.

[168]  Luoping Zhang,et al.  Biomarkers of COVID-19 and technologies to combat SARS-CoV-2 , 2020, Advances in Biomarker Sciences and Technology.

[169]  Elizabeth M Margolskee,et al.  Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2–associated multisystem inflammatory syndrome , 2020, Blood.

[170]  R. Crazzolara,et al.  SARS‐CoV‐2 infection in a 7‐year‐old girl with pancytopenia during acute lymphocytic leukemia maintenance therapy , 2020, Pediatric blood & cancer.

[171]  S. Başcı,et al.  The outcome of COVID‐19 in patients with hematological malignancy , 2020, Journal of medical virology.

[172]  M. Tunis,et al.  A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients. , 2020, Vaccine.

[173]  H. Ejaz,et al.  COVID-19 and comorbidities: Deleterious impact on infected patients , 2020, Journal of Infection and Public Health.

[174]  M. Libra,et al.  Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial? , 2020, Cancers.

[175]  G. Weiss,et al.  Prevalence and Predictive Value of Anemia and Dysregulated Iron Homeostasis in Patients with COVID-19 Infection , 2020, Journal of clinical medicine.

[176]  Tyler S. Severance,et al.  COVID‐19 and hereditary spherocytosis: A recipe for hemolysis , 2020, Pediatric blood & cancer.

[177]  E. Andrès,et al.  Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series , 2020, British journal of haematology.

[178]  S. Jagannath,et al.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward , 2020, Journal of Hematology & Oncology.

[179]  S. Basu,et al.  Haematological manifestations of COVID‐19: From cytopenia to coagulopathy , 2020, European journal of haematology.

[180]  F. Pasin,et al.  Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma , 2020, Acta bio-medica : Atenei Parmensis.

[181]  Jian Huang,et al.  Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up , 2020, Frontiers in Oncology.

[182]  N. Abraham,et al.  Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm , 2020, Antioxidants.

[183]  A. Shrivastava,et al.  Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi. , 2020, The Journal of the Association of Physicians of India.

[184]  L. Santos.  Can vitamin B12 be an adjuvant to COVID-19 treatment? , 2020, GSC Biological and Pharmaceutical Sciences.

[185]  G. Sucak,et al.  Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic , 2020, Rheumatology International.

[186]  G. Faulhaber,et al.  Systematic review about etiologic association to the leukoerythroblastic reaction , 2020, International journal of laboratory hematology.

[187]  F. Ferrara,et al.  Impact of Covid-19 on the treatment of acute myeloid leukemia , 2020, Leukemia.

[188]  J. Heemskerk,et al.  Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding , 2020, Haematologica.

[189]  O. Franco,et al.  Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis , 2020, European Journal of Epidemiology.

[190]  C. Ruiz,et al.  SARS-CoV-2 infection: The role of cytokines in COVID-19 disease , 2020, Cytokine & Growth Factor Reviews.

[191]  A. Allegra,et al.  Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges , 2020, Cancers.

[192]  G. Grant,et al.  The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities , 2020, Viruses.

[193]  G. G. Loscocco.  Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 , 2020, International Journal of Hematology.

[194]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[195]  Jun Yu Li,et al.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[196]  R. Pranata,et al.  Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis , 2020, Journal of Intensive Care.

[197]  J. Aguado,et al.  Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies , 2020, European journal of haematology.

[198]  G. Duan,et al.  Laboratory Abnormalities in Pregnant Women with Novel Coronavirus Disease 2019 , 2020, American Journal of Perinatology.

[199]  J. Rothman,et al.  How I approach hereditary hemolytic anemia and splenectomy , 2020, Pediatric blood & cancer.

[200]  Sheng-Jie Yu,et al.  Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments , 2020, Oncology letters.

[201]  M. Merino,et al.  A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection? , 2020, Lung Cancer.

[202]  A. Baruchel,et al.  COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE) , 2020, Bulletin du Cancer.

[203]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[204]  A. E. Eşkazan.  Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic , 2020, British journal of clinical pharmacology.

[205]  D. Shibata,et al.  Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations , 2020, Annals of Surgical Oncology.

[206]  D. McGonagle,et al.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.

[207]  Yanbing Ding,et al.  The epidemiology, diagnosis and treatment of COVID-19 , 2020, International Journal of Antimicrobial Agents.

[208]  M. Schivo,et al.  Leukoerythroblastic reaction in a patient with COVID‐19 infection , 2020, American journal of hematology.

[209]  Wenzhong Liu,et al.  COVID-19:Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism , 2020 .

[210]  L. Silvestri,et al.  Iron metabolism and iron disorders revisited in the hepcidin era , 2020, Haematologica.

[211]  S. Rutella,et al.  Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α , 2020, Journal of Translational Medicine.

[212]  J. Seghatchian,et al.  Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). , 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[213]  F. Slack,et al.  miR-155 as a novel clinical target for hematological malignancies. , 2019, Carcinogenesis.

[214]  S. Dalia,et al.  Venetoclax: evidence to date and clinical potential , 2019, Drugs in context.

[215]  L. Young,et al.  An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. , 2019, Blood.

[216]  L. Cámpora,et al.  Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. , 2019, The Lancet. Infectious diseases.

[217]  Md. Asiful Islam,et al.  Hyperferritinaemia: An Iron Sword of Autoimmunity. , 2019, Current pharmaceutical design.

[218]  J. Hernández-Boluda,et al.  Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety , 2019, Front. Oncol..

[219]  Jae Hoon Lee,et al.  MiR-150-5p May Contribute to Pathogenesis of Human Leiomyoma via Regulation of the Akt/p27Kip1 Pathway In Vitro , 2019, International journal of molecular sciences.

[220]  B. Wolffenbuttel,et al.  The Many Faces of Cobalamin (Vitamin B12) Deficiency , 2019, Mayo Clinic proceedings. Innovations, quality & outcomes.

[221]  S. Montoto,et al.  The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies , 2019, Bone Marrow Transplantation.

[222]  L. Medeiros,et al.  Chronic Myeloid Leukemia: Beyond BCR-ABL1 , 2018, Current Hematologic Malignancy Reports.

[223]  A. Zeidan,et al.  Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts , 2018, European journal of haematology.

[224]  P. Brissot,et al.  Rare anemias due to genetic iron metabolism defects. , 2018, Mutation research.

[225]  B. Baradaran,et al.  PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b , 2018, Advanced pharmaceutical bulletin.

[226]  J. Hernández-Rivas,et al.  New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update , 2018, Cancers.

[227]  E. Hawkes,et al.  Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies , 2018, Journal of clinical medicine.

[228]  E. Belongia,et al.  Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[229]  M. Cilli,et al.  Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence , 2018, Science Translational Medicine.

[230]  Aifei Liu,et al.  [Research Progress on miR-125 Family in Malignant Hematologic Diseases-Review]. , 2017, Zhongguo shi yan xue ye xue za zhi.

[231]  C. Cunningham-Rundles,et al.  Idiopathic CD4 lymphocytopenia: Pathogenesis, etiologies, clinical presentations and treatment strategies. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[232]  T. Sanda,et al.  TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. , 2017, Experimental hematology.

[233]  Simona Manciu,et al.  Hereditary Spherocytosis - Diagnosis, Surgical Treatment and Outcomes. A Literature Review. , 2017, Chirurgia.

[234]  J. Zachary,et al.  Mechanisms and Morphology of Cellular Injury, Adaptation, and Death , 2017, Pathologic Basis of Veterinary Disease.

[235]  M. Nolte,et al.  Impact of Viral Infections on Hematopoiesis: From Beneficial to Detrimental Effects on Bone Marrow Output , 2016, Front. Immunol..

[236]  J. McCubrey,et al.  Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. , 2016, Biochimica et biophysica acta.

[237]  D. Grimwade,et al.  Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. , 2016, Blood.

[238]  C. Croce,et al.  Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML) , 2015 .

[239]  Q. Hill,et al.  Autoimmune hemolytic anemia. , 2015, Hematology. American Society of Hematology. Education Program.

[240]  R. Ware,et al.  Hydroxyurea therapy for sickle cell anemia , 2015, Expert opinion on drug safety.

[241]  M. Sigvardsson,et al.  Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. , 2015, Blood.

[242]  J. Kerr.  A review of blood diseases and cytopenias associated with human parvovirus B19 infection , 2015, Reviews in medical virology.

[243]  A. Tefferi,et al.  Definition and management of ruxolitinib treatment failure in myelofibrosis , 2014, Blood Cancer Journal.

[244]  S. Ševčíková,et al.  The miR-29 family in hematological malignancies. , 2014, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[245]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[246]  Y. Shoenfeld,et al.  The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome , 2013, BMC Medicine.

[247]  S. Masters,et al.  miR‐223: infection, inflammation and cancer , 2013, Journal of internal medicine.

[248]  X. Hua,et al.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. , 2013, Carcinogenesis.

[249]  N. Munshi,et al.  Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.

[250]  S. Ševčíková,et al.  Serum miR-29a as a marker of multiple myeloma , 2013, Leukemia & lymphoma.

[251]  M. Negrini,et al.  Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.

[252]  Noam Shomron,et al.  Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells , 2012, PloS one.

[253]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[254]  P. Starostik,et al.  Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. , 2011, Leukemia research.

[255]  X. Leleu,et al.  Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia , 2011, Leukemia.

[256]  D. Dexter,et al.  Iron and the immune system , 2011, Journal of Neural Transmission.

[257]  B. Gerber,et al.  [Autoimmune hemolytic anemia]. , 2010, Therapeutische Umschau. Revue therapeutique.

[258]  J. V. Von Roenn,et al.  Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. , 2010, Blood.

[259]  S. Shulman,et al.  Pathogenesis and management of Kawasaki disease , 2010, Expert review of anti-infective therapy.

[260]  M. Björkholm,et al.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. , 2008, Blood.

[261]  W. Murphy,et al.  Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.

[262]  A. Marengo-Rowe.  The Thalassemias and Related Disorders , 2007, Proceedings.

[263]  S. Fischer,et al.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. , 2006, Blood.

[264]  T. Ganz,et al.  Regulation of iron metabolism by hepcidin. , 2006, Annual review of nutrition.

[265]  P. Malik,et al.  Pathophysiology and therapy for haemoglobinopathies; Part II: thalassaemias , 2006, Expert Reviews in Molecular Medicine.

[266]  D. Combs,et al.  Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial , 2005, Journal of clinical pharmacology.

[267]  M. Gladwin,et al.  Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension , 2005, British journal of haematology.

[268]  E. Shapiro,et al.  Association between a Novel Human Coronavirus and Kawasaki Disease , 2005, The Journal of infectious diseases.

[269]  A. Gow,et al.  Loss of α-hemoglobin–stabilizing protein impairs erythropoiesis and exacerbates β-thalassemia , 2004 .

[270]  M. Ishii,et al.  Re‐treatment for immune globulin‐resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy , 2001, Pediatrics international : official journal of the Japan Pediatric Society.

[271]  K. Hirokawa,et al.  Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.

[272]  M. Freed,et al.  Special Report Diagnosis and Therapy of Kawasaki Disease in Children , 1993, Circulation.

[273]  J. Pacala.  Vitamin B12 deficiency. , 1993, The Journal of family practice.

[274]  R. Neiman,et al.  Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. , 1985, Blood.

[275]  S. Schwartz,et al.  Splenectomy for hematologic disorders. , 1970, Archives of surgery.

[276]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[277]  Neha Khatri,et al.  Pancytopenia in pregnant patients with COVID-19 infection and vitamin B12 deficiency: a case report study , 2021, Journal of Ideas in Health.

[278]  L. Allen.  Efficacy and Safety of Vitamin B12 Fortification , 2018 .

[279]  V. D’Agati,et al.  An unusual cause of hypertension with hematuria and proteinuria: Answers , 2016, Pediatric Nephrology.

[280]  J. Scott,et al.  Partial splenectomy for hereditary spherocytosis: a multi-institutional review. , 2011, Journal of pediatric surgery.

[281]  G. E. Simon,et al.  The measurement of free erythrocyte porphyrin (FEP) as a simple means of distinguishing iron deficiency from beta-thalassemia trait in subjects with microcytosis. , 1975, The Journal of laboratory and clinical medicine.